Which statements describe the offer, and which require evidence about the actual preparation?
Open dossier ↗Volume 01 / Evidence & interpretation / October 2026
Read past
the headline.
Behind every treatment number is a question about who was studied, what was measured and what the result can actually support.
Read the evidence notePrecise numbers deserve
equally precise context.
The evidence notes.
A 20% lower hazard is not a 20-point difference
Reading the SELECT cardiovascular trial without confusing a relative measure, an observed proportion and a personal forecast.
Read the note ↗02Evidence note 02Why a safety-report count is not an event rate
Reports can reveal important signals without providing a denominator, a causal verdict or a fair ranking of medicines.
Read the note ↗03Evidence note 03When a study result becomes a marketing claim
Follow the chain from the original research to the product, population and service being advertised.
Read the note ↗04Evidence methodsA composite endpoint contains more than one outcome
Before repeating a cardiovascular claim, identify what counted as an event and how the result was measured.
Read the note ↗05Research appraisalRead the funding statement, then keep reading the methods
Sponsorship is relevant context. It does not replace examination of the study question, design and reporting.
Read the note ↗06Reading boundariesWhat you can responsibly take from a trial abstract
An abstract can orient a reader while leaving important methods and results outside the available view.
Read the note ↗07Scientific articleESSENCE and MASH: Reading the Biopsy Evidence Before Long-Term Outcomes
The 72-week ESSENCE analysis found meaningful biopsy improvements with weekly injectable semaglutide. Its accelerated MASH approval rests on those findings, while longer follow-up addresses liver complications and survival.
Read the note ↗08Scientific articleOral Orforglipron in ATTAIN-1: Weight Results, Safety, and Formulation
The 72-week trial established a weight-loss benefit over placebo. Interpreting that benefit requires separating study doses from marketed tablets, averages from individual responses, and clinical evidence from care-plan claims.
Read the note ↗The care dossiers.
Does the dated promotion match the complete offer presented at checkout?
Open dossier ↗Is the comparison using a monthly charge, a term total or a monthly equivalent?
Open dossier ↗Which evidence belongs to the medication, and which describes the membership service?
Open dossier ↗Does a cited result evaluate this exact program, or only a component of treatment?
Open dossier ↗Which organization supplies the care, which supplies the medicine and which sets each charge?
Open dossier ↗Which claims on the Hers offer are medicine evidence and which concern the service itself?
Open dossier ↗Does the research cited for an ingredient match Henry’s proposed formulation?
Open dossier ↗What population and analysis support Calibrate’s program-results claims?
Open dossier ↗Are Sesame’s displayed weight-loss milestones platform outcomes or summaries of drug research?
Open dossier ↗When does my next charge process, what happens to an unused prepaid balance, and who handles my clinical follow-up?
Open dossier ↗Which state list, consultation format, pharmacy and refund agreement apply to my current one-time package?
Open dossier ↗